Blanco-Vega Dulce D, Reyes-López Alfonso, Vargas-Neri Jessica L, Osnaya-Valencia Frida I
Department of Epidemiological Research, Hospital Infantil de México Federico Gómez, Mexico City 06720, Mexico.
Faculty of Chemistry, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
Pharmacy (Basel). 2024 Sep 27;12(5):148. doi: 10.3390/pharmacy12050148.
In Mexico, type 2 diabetes mellitus (T2DM) is a serious public health concern. As experts in drug therapy, pharmacists are essential additions to multidisciplinary diabetes patient care teams. There have been no systematic reviews or meta-analyses performed on pharmacist-led interventions (PIs) in Mexico; therefore, the impact of PIs on patients remains poorly explored. An electronic search of the PubMed, SciELO and BVS databases and certain institutional repositories was conducted in English and Spanish through 24 August 2021 with a subsequent update through June 2024. A total of 1302 potentially relevant studies were identified in the initial search, of which nine met the eligibility criteria and were included in this systematic review. The results suggest that PIs, such as pharmacotherapeutic follow-up and patient education, may have positive effects on outcomes in Mexican patients with T2DM. PIs led to significant reductions in glycosylated hemoglobin, fasting blood glucose, triglycerides, total cholesterol, LDL cholesterol and arterial blood pressure levels, general reductions in body mass index and negative outcomes associated with medication, as well as significant improvements in therapeutic adherence and patient knowledge in the intervention group during follow-up periods of 3-12 months. Further well-designed research, including controlled studies with adequate sample sizes and standardized tools, is essential to fully understand the effects of PIs regarding patients with T2DM in Mexico.
在墨西哥，2型糖尿病（T2DM）是一个严重的公共卫生问题。作为药物治疗方面的专家，药剂师是多学科糖尿病患者护理团队中不可或缺的成员。墨西哥尚未对药剂师主导的干预措施（PI）进行系统评价或荟萃分析；因此，PI对患者的影响仍未得到充分探讨。通过在PubMed、SciELO和BVS数据库以及某些机构知识库中进行电子检索，检索语言为英语和西班牙语，检索截止日期为2021年8月24日，随后更新至2024年6月。在初步检索中总共识别出1302项潜在相关研究，其中9项符合纳入标准并被纳入本系统评价。结果表明，诸如药物治疗随访和患者教育等PI可能对墨西哥T2DM患者的治疗结果产生积极影响。在3至12个月的随访期内，PI导致干预组糖化血红蛋白、空腹血糖、甘油三酯、总胆固醇、低密度脂蛋白胆固醇和动脉血压水平显著降低，体重指数总体下降，与药物相关的不良后果减少，治疗依从性和患者知识水平显著提高。进一步开展设计良好的研究，包括具有足够样本量和标准化工具的对照研究，对于全面了解PI对墨西哥T2DM患者的影响至关重要。
